Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset

HUNTINGDON, U.K. - April 13, 2015 - PRLog -- Designed to be used by patients at home and by clinicians at the bedside of patients in hospitals. This will open up opportunities for the Company to partner with pharmaceutical companies in the US to act as a distributor for the Sputum test.

The Patent granted to Aseptika in the US (Patent US8980566B2), with other worldwide applications taking place under the International Patent Treaty expected to be granted in the near future. The Patent determines the levels of activity of bacteria in the lungs of vulnerable patients with long-term conditions, such as Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and Asthma.

The presence of two very different materials (biomarkers) produced by the bacterium (Pseudomonas aeruginosa (http://www.activ8rlives.com/solutions/clinical-trials/)) are described, in which the levels of a marker for a bacterial iron scavenging process and levels of a secreted bacterial protein are measured over time. Changes in these concentrations allow levels of bacterial activity to be determined and exacerbations of bacterial infection to be predicted and/or monitored. The methods of the invention may also be used for monitoring effectiveness of antibiotic treatment of lung infection.

The biomarker test is currently being used in the SBRI Healthcare (http://www.sbrihealthcare.co.uk/case-studies/aseptika/)-fundedSENSOR clinical trial (http://www.activ8rlives.com/sensor/) in collaboration with Portsmouth Hospitals NHS Trust (http://www.porthosp.nhs.uk/departments/Research/Research-Department.htm), with volunteers who have COPD and severe Asthma and it is hoped to make a home-use version available within the next year.

- Ends -

About Aseptika Limited (Activ8rlives):

Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by laypeople and their healthcare service providers to better self-manage (http://www.activ8rlives.com/solutions/self-monitoring-and-self-management.html) long-term health conditions (LTHC) through self-monitoring.

The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do.

Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.

The Company gained the UK patent in 2013 protecting the invention of a test for biomarkers (http://www.activ8rlives.com/about/news-and-events/news/2013/10/07/aseptika-awarded-uk-patent-for-home-test-for-lung-infections/) of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient.

Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME”eHealth solution 2014 (http://www.activ8rlives.com/about/news-and-events/news/2014/04/03/aseptika-wins-first-place-for-most-promising-ehealth-solution-competition-2014/#sthash.jm6jQb3Q.dpuf)developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease (http://www.activ8rlives.com/solutions/clinical-trials/), providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospital-at-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs which from time to time, flare into a full and repeated chest infections.

Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 (http://www.cambridge-news.co.uk/Innovations-2014/story-22802672-detail/story.html). Winner of the Discovery Start-up 2014 Competition (http://www.cambridgewireless.co.uk/news/article/default.aspx?objid=47697) run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014 (http://www.huntsbusinessawards.co.uk/). Named on Global Digital Health 100 Award (http://www.thejournalofmhealth.com/#!The-Journal-of-mHealth-Announces-the-2014-Global-Digital-Health-100-Recognising-the-Most-Innovative-Digital-Companies-in-Healthcare/cuhk/8C07B55F-084F-4C3E-BD3D-4A63343372FA) list, reflecting the importance of mobile and digital solutions.

AXA PPP Health Tech & You (http://tr.axa-ppp.co.uk/do?B1D6C55B52E4CA5F29BAC297AFEC96616BEED2ADFC11507352CB0B093683219668A1A1FDC5BE1F9AAFCFBA515D62693465C0057B22D451DBCA5F71EBBA9990A9) Awards selected Aseptika as the Winner of the “Manage My Condition” category.

Wearable Technology Awards 2015 (http://www.wearabletechnologyshow.net/awards) Aseptika was shortlisted in three categories: Best Innovation, Overall Wearable Winner and was placed third in the Best Medical Device category.

For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com

Activ8rlives, Activ8rlives.com, BuddyWOTCH and EyKos are trademarks of Aseptika Ltd.

For press information, please contact:

Jessica Auton, Marketing Director

jessica.auton@aseptika.com

Direct +44 (0)1480 352 821

Mobile +44 (0)7455 922 122